Related Experiment Video

Updated: Aug 11, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Acute leukemia after chemotherapy (melphalan)

N Einhorn

    Cancer
    |February 1, 1978
    PubMed

    Abstract:

    During the years 1966-1973 474 patients with ovarian carcinoma were treated with melphalan. Of these, 48 patients received at least 300 mg melphalan and survived at least 3 years; four cases of acute leukemia were found among these 48 patients. All cases belonged to a group of 12 cases receiving 800 mg melphalan or more.

    More Related Videos

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Aug 11, 2026

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
    09:02

    Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

    Published on: July 31, 2016

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Concept Videos

    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Bone Marrow Sampling and Transplants01:22

    Bone Marrow Sampling and Transplants

    Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
    The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

    Articles linked to this work by shared authors, journal, and citation graph.

    Gain of chromosome 3q is an early and consistent genetic aberration in carcinomas of the vulva.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005

    Laminin-5 gamma 2 chain as an invasivity marker for uni- and multifocal lesions in the lower anogenital tract.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2002

    Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.

    European journal of cancer (Oxford, England : 1990)·2001

    D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.

    Anti-cancer drugs·2001

    Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

    Lancet (London, England)·2001

    Long-term follow-up of the Stockholm screening study on ovarian cancer.

    Gynecologic oncology·2000

    External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

    Cancer·2026

    Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.

    Cancer·2026

    Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

    Cancer·2026

    Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.

    Cancer·2026

    Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation-The Peachtree Consensus.

    Cancer·2026

    Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer.

    Cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us